A Phase 3 interventional study of Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r) and Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) in Infection, Human Immunodeficiency Virus I and HIV Infection, sponsored by ViiV Healthcare. Completed at 72 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-22.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.
Among the 57 studies testing abacavir in HIV Infections, this one is the 4th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2007, is one of 16 in phase 3, and was the 46th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:
University College, London
Ages 4 wk–14 yrs
Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 78 across the 50 interventional studies. Of the 50 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2007, is one of 65 in phase 3, and was the 114th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 57 studies testing abacavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by randomization to either a simplification regimen of ATV or continuation of ATV +/r for an additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1 infected, HLA-B*5701 negative subjects.
All subjects who complete the 84-week study will be eligible to enter the treatment extension phase and continue for an additional 60 weeks. The purpose of this extension is to obtain longer term treatment data in subjects who have completed the 84-week study.
Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 515 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Eligibility Criteria for Treatment Extension Phase:
-Subjects will be eligible to continue in the treatment extension phase (Weeks 84 to 144) if they have successfully completed the 84-week study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
Drug pages: Abacavir · Lamivudine · Atazanavir · Ritonavir
Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Drug pages: Abacavir · Lamivudine · Atazanavir
Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit
The percentage of PAR with HIV-1 RNA virus \<50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (\<100,000 c/ml and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.
Time frame: Week 84
Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase
The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.
Time frame: Baseline of Randomized Phase
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 36 Visit
The percentage of PAR with HIV-1 RNA virus \<50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.
Time frame: Week 36
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 84 Visit
A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA \<50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.
Time frame: Week 84
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 144 Visit
Percentage of PAR with HIV-1 RNA \<50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
Time frame: Week 144
Percentage of Participants Who Achieved Plasma HIV-1 RNA <400 c/ml at the Week 36 Visit
The percentage of PAR with HIV-1 RNA virus \<400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
Time frame: Week 36
Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 84 Visit
Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
Time frame: Week 84
Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 144 Visit
Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
Time frame: Week 144
Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36
The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
Time frame: Week 36
Number of Participants Who Met the PDVF Criteria at Week 84
The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
Time frame: Week 84
Number of Participants Who Met the PDVF Criteria at Week 144
The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
Time frame: Week 144
Change From Baseline in HIV-1 RNA at Week 36
Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
Time frame: Baseline and Week 36
Change From Baseline in HIV-1 RNA at Week 84
Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
Time frame: Baseline and Week 84
Change From Baseline in HIV-1 RNA at Week 144
Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
Time frame: Baseline and Week 144
Change From Baseline in CD4+ Cell Count at Week 36
Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.
Time frame: Baseline and Week 36
Change From Baseline in CD4+ Cell Count at Week 84
A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.
Time frame: Baseline and Week 84
Change From Baseline in CD4+ Cell Count at Week 144
A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.
Time frame: Baseline and Week 144
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Time frame: Baseline through Week 36
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Time frame: Randomization at Week 36 through Week 84
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Time frame: Week 84 through Week 144
Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
Time frame: Baseline through Week 36
Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
Time frame: Randomization at Week 36 through Week 84
Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
Time frame: Week 84 through Week 144
Mean Percent Compliance at Week 36
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
Time frame: Week 36
Mean Percent Compliance at Week 84
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
Time frame: Week 84
Mean Percent Compliance at Week 144
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
Time frame: Week 144
Participants (PAR) were recruited at 66 centers in the United States of America and Canada. HIV-RNA, human immunodeficiency virus-ribonucleic acid; ml, milliliters.
| Milestone | ABC/3TC + ATV/r: Induction Phase | ABC/3TC + ATV: Randomization Phase | ABC/3TC + ATV/r: Randomization Phase | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|---|---|---|
| Started | 515 | 0 | 0 | 0 | 0 |
| Completed | 442 | 0 | 0 | 0 | 0 |
| Not completed | 73 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Insufficient viral load response | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol-defined virologic failure | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Kaposi lesions requiring chemotherapy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Took exclusionary medications | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Genotype had exclusionary mutations | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Fleeing police; outstanding warrants | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Incarceration | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Milestone | ABC/3TC + ATV/r: Induction Phase | ABC/3TC + ATV: Randomization Phase | ABC/3TC + ATV/r: Randomization Phase | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|---|---|---|
| Started | 0 | 210 | 209 | 0 | 0 |
| Completed | 0 | 194 | 185 | 0 | 0 |
| Not completed | 0 | 16 | 24 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 5 | 0 | 0 |
| Withdrew: Protocol-defined virologic failure | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 3 | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 8 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 4 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Incarceration | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Trying to get pregnant | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 |
| Milestone | ABC/3TC + ATV/r: Induction Phase | ABC/3TC + ATV: Randomization Phase | ABC/3TC + ATV/r: Randomization Phase | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 189 | 180 |
| Completed | 0 | 0 | 0 | 160 | 154 |
| Not completed | 0 | 0 | 0 | 29 | 26 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Insufficient viral load response | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol-defined virologic failure | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 9 | 9 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Participant moved | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Sponsor request | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Sponsor terminated site | 0 | 0 | 0 | 3 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant remained in cuba | 0 | 0 | 0 | 0 | 1 |
The percentage of PAR with HIV-1 RNA virus \<50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (\<100,000 c/ml and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.
| percentage of participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit | 86 | 81 |
The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.
| years | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase | 37.5 ± 10.23 | 39.7 ± 9.71 |
The percentage of PAR with HIV-1 RNA virus \<50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.
| percentage of participants | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| TLOVR | 80 |
| Obs | 88 |
| M/D=F | 77 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA \<50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.
| percentage of participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Obs | 92 | 92 |
| M/D=F | 85 | 82 |
Percentage of PAR with HIV-1 RNA \<50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
| percentage of participants | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| TLOVR | 77 | 73 |
| Obs | 95 | 92 |
| M/D=F | 80 | 78 |
The percentage of PAR with HIV-1 RNA virus \<400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
| percentage of participants | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| TLOVR | 82 |
| Obs | 98 |
| M/D=F | 84 |
Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
| percentage of participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| TLOVR | 92 | 86 |
| Obs | 99 | 98 |
| M/D=F | 92 | 87 |
Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.
| percentage of participants | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| TLOVR | 84 | 80 |
| Obs | 99 | 97 |
| M/D=F | 84 | 82 |
The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
| participants | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| Protocol-defined virologic failure | 15 |
| Failure to achieve <400 c/ml by Week 30 | 5 |
| Confirmed rebound after achieving <400 c/ml | 10 |
The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
| participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Protocol-defined virologic failure | 1 | 7 |
| Confirmed rebound after achieving <400 c/ml | 1 | 7 |
The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.
| participants | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| Protocol-defined virologic failure | 5 | 6 |
| Confirmed rebound after achieving <400 c/ml | 5 | 6 |
Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
| log10 c/ml | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| Change From Baseline in HIV-1 RNA at Week 36 | -3.241 ± 0.775 |
Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
| log10 c/ml | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Change From Baseline in HIV-1 RNA at Week 84 | -3.261 ± 0.681 | -3.270 ± 0.698 |
Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.
| log10 c/ml | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| Change From Baseline in HIV-1 RNA at Week 144 | -3.291 ± 0.675 | -3.239 ± 0.835 |
Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.
| cells/millimeters cubed (mm^3) | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| Change From Baseline in CD4+ Cell Count at Week 36 | 185.4 ± 121.84 |
A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.
| cells/millimeters cubed (mm^3) | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 84 | 265.7 ± 157.65 | 282.9 ± 150.49 |
A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.
| cells/millimeters cubed (mm^3) | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 144 | 317.7 ± 161.98 | 325.1 ± 178.29 |
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
| participants | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| PAR with paired genotypes at baseline and VF | 15 |
| PAR with treatment-emergent mutations | 6 |
| PAR with NRTI mutations | 4 |
| PAR with NNRTI mutations | 1 |
| PAR with major PI mutations | 0 |
| PAR with minor PI mutations | 2 |
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
| participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| PAR with paired genotypes at baseline and VF | 1 | 7 |
| PAR with treatment-emergent mutations | 1 | 2 |
| PAR with NRTI mutations | 1 | 0 |
| PAR with NNRTI mutations | 0 | 0 |
| PAR with major PI mutations | 0 | 0 |
| PAR with minor PI mutations | 0 | 2 |
A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
| participants | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| PAR with paired genotypes at baseline and VF | 5 | 5 |
| PAR with treatment-emergent mutations | 2 | 1 |
| PAR with NRTI mutations | 0 | 1 |
| PAR with NNRTI mutations | 0 | 0 |
| PAR with major PI mutations | 0 | 1 |
| PAR with minor PI mutations | 2 | 1 |
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
| participants | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| PAR with reduced abacavir susceptibility | 0 |
| PAR with reduced lamivudine susceptibility | 1 |
| PAR with reduced atazanavir susceptibility | 0 |
| PAR with reduced ritonavir susceptibility | 0 |
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
| participants | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| PAR with reduced abacavir susceptibility | 0 | 0 |
| PAR with reduced lamivudine susceptibility | 1 | 0 |
| PAR with reduced atazanavir susceptibility | 0 | 0 |
| PAR with reduced ritonavir susceptibility | 0 | 0 |
A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.
| participants | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| PAR with reduced abacavir susceptibility | 0 | 1 |
| PAR with reduced lamivudine susceptibility | 1 | 1 |
| PAR with reduced atazanavir susceptibility | 0 | 1 |
| PAR with reduced ritonavir susceptibility | 0 | 1 |
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
| percent compliance | ABC/3TC + ATV/r: Induction Phase |
|---|---|
| Abacavir/Lamivudine | 92.2 ± 13.05 |
| Ritonavir | 92.3 ± 12.15 |
| Atazanavir | 92.7 ± 12.50 |
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
| percent compliance | ABC/3TC + ATV: Randomized Phase | ABC/3TC + ATV/r: Randomized Phase |
|---|---|---|
| Abacavir/Lamivudine | 92.0 ± 11.62 | 91.2 ± 13.49 |
| Ritonavir | 92.9 ± 11.64 | 91.5 ± 12.23 |
| Atazanavir | 98.9 ± 5.32 | 92.4 ± 11.89 |
Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.
| percent compliance | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|
| Abacavir/Lamivudine | 92.0 ± 12.65 | 90.1 ± 15.35 |
| Ritonavir | 93.3 ± 11.07 | 90.1 ± 14.58 |
| Atazanavir | 99.1 ± 4.54 | 91.4 ± 13.99 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABC/3TC + ATV/r: Induction Phase | — | 39/515 (7.6%) | 237/515 (46%) |
| ABC/3TC + ATV: Randomization Phase | — | 22/210 (10.5%) | 116/210 (55.2%) |
| ABC/3TC + ATV/r: Randomization Phase | — | 22/209 (10.5%) | 123/209 (58.9%) |
| ABC/3TC + ATV: Extension Phase | — | 24/189 (12.7%) | 123/189 (65.1%) |
| ABC/3TC + ATV/r: Extension Phase | — | 24/180 (13.3%) | 130/180 (72.2%) |
| Event | ABC/3TC + ATV/r: Induction Phase | ABC/3TC + ATV: Randomization Phase | ABC/3TC + ATV/r: Randomization Phase | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|---|---|---|
| Drug hypersensitivityImmune system disorders | 5/515 | 2/210 | 3/209 | 1/189 | 4/180 |
| CellulitisInfections and infestations | 1/515 | 2/210 | 0/209 | 4/189 | 0/180 |
| AppendicitisInfections and infestations | 3/515 | 2/210 | 1/209 | 1/189 | 2/180 |
| Cerebrovascular accidentNervous system disorders | 1/515 | 0/210 | 2/209 | 0/189 | 2/180 |
| BronchitisInfections and infestations | 1/515 | 0/210 | 1/209 | 2/189 | 0/180 |
| NauseaGastrointestinal disorders | 1/515 | 1/210 | 0/209 | 2/189 | 0/180 |
| VomitingGastrointestinal disorders | 1/515 | 1/210 | 0/209 | 2/189 | 0/180 |
| Non-cardiac chest painGeneral disorders | 0/515 | 1/210 | 0/209 | 2/189 | 0/180 |
| Appendicitis, perforatedInfections and infestations | 0/515 | 1/210 | 1/209 | 1/189 | 1/180 |
| PneumoniaInfections and infestations | 2/515 | 0/210 | 1/209 | 1/189 | 1/180 |
| Event | ABC/3TC + ATV/r: Induction Phase | ABC/3TC + ATV: Randomization Phase | ABC/3TC + ATV/r: Randomization Phase | ABC/3TC + ATV: Extension Phase | ABC/3TC + ATV/r: Extension Phase |
|---|---|---|---|---|---|
| SinusitisInfections and infestations | 21/515 | 15/210 | 19/209 | 19/189 | 25/180 |
| Blood bilirubin increasedHepatobiliary disorders | 40/515 | 20/210 | 22/209 | 22/189 | 24/180 |
| DiarrhoeaGastrointestinal disorders | 42/515 | 24/210 | 23/209 | 25/189 | 21/180 |
| BronchitisInfections and infestations | 18/515 | 11/210 | 22/209 | 20/189 | 22/180 |
| HyperbilirubinaemiaHepatobiliary disorders | 30/515 | 14/210 | 20/209 | 14/189 | 20/180 |
| Upper respiratory tract infectionInfections and infestations | 16/515 | 13/210 | 16/209 | 20/189 | 19/180 |
| DepressionPsychiatric disorders | 18/515 | 11/210 | 10/209 | 11/189 | 15/180 |
| InsomniaPsychiatric disorders | 17/515 | 6/210 | 11/209 | 11/189 | 13/180 |
| NauseaGastrointestinal disorders | 24/515 | 12/210 | 10/209 | 9/189 | 12/180 |
| SyphilisInfections and infestations | 7/515 | 5/210 | 7/209 | 12/189 | 10/180 |
| Age Continuous(Years) | ABC/3TC + ATV/r |
|---|---|
| Mean | 38.3 ± 10.03 |
| Sex: Female, Male(Participants) | ABC/3TC + ATV/r |
|---|---|
| Female | 86 |
| Male | 429 |
| Race/Ethnicity, Customized(participants) | ABC/3TC + ATV/r |
|---|---|
| African American/African Heritage | 167 |
| American Indian or Alaskan Native | 9 |
| Asian - Central/South Asian Heritage | 4 |
| Asian - East Asian Heritage | 3 |
| Asian - Japanese Heritage | 1 |
| Asian - South East Asian Heritage | 3 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White - Arabic/North African Heritage | 5 |
| White - White/Caucasian/European Heritage | 316 |
| Mixed Race | 6 |
| Number of participants with the indicated baseline HIV-RNA level(participants) | ABC/3TC + ATV/r |
|---|---|
| HIV-1 RNA <100,000 | 227 |
| HIV-1 RNA 100,000-<250,000 | 143 |
| HIV-1 RNA 250,000-<500,000 | 73 |
| HIV-1 RNA >=500,000 | 72 |
| Number of participants with the indicated Baseline CD4+ Cell Count(participants) | ABC/3TC + ATV/r |
|---|---|
| CD4+ cells <50 | 69 |
| CD4+ cells 50-<200 | 190 |
| CD4+ cells >=200 | 256 |
| Number of participants with the indicated Center for Disease Control (CDC) Classification(participants) | ABC/3TC + ATV/r |
|---|---|
| Asymptomatic HIV Infection | 353 |
| Symptomatic (non-AIDS) condition | 97 |
| AIDS | 65 |
| Median Baseline CD4+ Cell Count(cells per cubic millimeter) | ABC/3TC + ATV/r |
|---|---|
| Median | 199 (19 to 754) |
| Median Baseline HIV-1 RNA Level(log10 copies/ml) | ABC/3TC + ATV/r |
|---|---|
| Median | 5.076 (2.989 to 6.620) |
The record gives a start of Mar 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 1 month after primary completion. A results delay was requested in May 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abacavir · Lamivudine · Atazanavir · Ritonavir